FDA approves first mRNA flu vaccine: what it means and why it matters

01How the mRNA flu vaccine works

An mRNA vaccine is a type of vaccine that uses a copy of a molecule called messenger RNA to produce an immune response. The vaccine delivers molecules of antigen-encoding mRNA into cells, which use the designed mRNA as a blueprint to build foreign protein that would normally be produced by a pathogen. The immune system then recognizes the protein as foreign and mounts an immune response against it.

For the flu vaccine, the mRNA encodes the hemagglutinin protein, a key surface protein of the influenza virus. Once the mRNA is delivered into cells via lipid nanoparticles, the cells produce the hemagglutinin protein, which the immune system recognizes as foreign. The immune response includes the production of antibodies and the activation of T cells, providing protection against future infection by influenza viruses that carry the same hemagglutinin protein.

The advantage of mRNA technology is that the vaccine can be designed as soon as the genetic sequence of the target pathogen is known. There is no need to grow the virus in eggs or cell cultures, a process that takes months for traditional flu vaccines. The mRNA can be synthesized chemically from the genetic sequence, and the lipid nanoparticles can be manufactured at scale. This dramatically shortens the production timeline.

02Why mRNA is faster than traditional vaccine production

Traditional influenza vaccine production relies on growing the virus in fertilized chicken eggs. The process takes approximately six months from the selection of vaccine strains to the delivery of finished vaccine. The virus must be adapted to grow in eggs, which can introduce mutations that reduce vaccine effectiveness. The egg-based process also requires hundreds of millions of eggs each year and is vulnerable to supply chain disruptions.

The mRNA vaccine production process is fundamentally different. Once the genetic sequence of the target influenza strain is identified, the mRNA can be synthesized in a matter of weeks. The lipid nanoparticle delivery system is manufactured separately and can be produced at scale. The entire production process, from sequence to finished vaccine, can take as little as four to six weeks, compared to six months for egg-based vaccines.

This speed advantage has implications for both seasonal and pandemic vaccination. For seasonal flu, faster production means the vaccine can be updated closer to flu season, improving the match between the vaccine and circulating strains. For pandemic response, the ability to produce a vaccine within weeks rather than months could save millions of lives by making the vaccine available before a pandemic reaches its peak.

03The FDA approval process and what it required

The Food and Drug Administration is a federal agency of the United States Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter drugs, vaccines, and medical devices. The approval of a new vaccine requires extensive clinical data demonstrating safety and effectiveness.

The mRNA flu vaccine approval required Phase 1, 2, and 3 clinical trials. Phase 1 trials tested safety and dosage in a small group of healthy volunteers. Phase 2 trials expanded the safety assessment and measured immune response in a larger group. Phase 3 trials, involving tens of thousands of participants, compared the mRNA flu vaccine to an existing approved flu vaccine, measuring both immune response and rates of laboratory-confirmed influenza.

The FDA reviewed the clinical data through its standard approval process, which includes evaluation by the Center for Biologics Evaluation and Research and review by the Vaccines and Related Biological Products Advisory Committee. The committee, composed of independent experts, evaluated the safety, effectiveness, and manufacturing quality data before recommending approval. The approval represents the first time an mRNA vaccine has been approved for seasonal influenza.

04Effectiveness compared to traditional flu vaccines

Influenza vaccines, colloquially known as flu shots, are vaccines that protect against infection by influenza viruses. New versions of the vaccines are developed twice a year, as the influenza virus rapidly changes. While their effectiveness varies from year to year, most provide modest to moderate protection against influenza.

The mRNA flu vaccine demonstrated improved effectiveness compared to traditional flu vaccines in clinical trials. The improved effectiveness is partly due to better antigen matching: because the mRNA can be updated quickly, the vaccine can be designed closer to flu season, when the circulating strains are better known. Traditional egg-based vaccines must commit to a strain selection months in advance, sometimes leading to mismatches.

Another factor is the immune response itself. mRNA vaccines tend to produce a stronger and more consistent immune response than traditional inactivated vaccines, particularly in older adults, who are among the most vulnerable to severe influenza. The mRNA platform also allows for the inclusion of multiple antigens, potentially providing broader protection against diverse influenza strains in a single vaccine.

05What this means for future vaccine development

The approval of the first mRNA flu vaccine opens the door to a broader range of mRNA vaccines. The mRNA platform is pathogen-agnostic: the same delivery system can be used to deliver mRNA encoding any protein antigen. This means that vaccines for other respiratory diseases, such as RSV, could be developed on the same platform, potentially as combination vaccines that protect against multiple pathogens in a single shot.

The speed and flexibility of mRNA technology also enables a new approach to vaccine design. Rather than developing a single vaccine for a single strain, researchers can design libraries of mRNA candidates targeting different variants and select the most effective based on rapid clinical testing. This approach, known as rapid iterative vaccine design, could produce more effective vaccines that are better matched to circulating pathogens.

The manufacturing scalability of mRNA vaccines is another advantage. Once the production infrastructure is established, producing mRNA vaccines for different pathogens requires only a change in the mRNA sequence, not a fundamentally different manufacturing process. This could lower the cost of vaccine production and make vaccines more accessible globally, particularly in low- and middle-income countries that have historically had limited access to new vaccines.

06The speed advantage for pandemic response

The COVID-19 pandemic demonstrated both the potential and the limitations of mRNA vaccine technology. The first mRNA vaccine was deployed within a year of the identification of the SARS-CoV-2 virus, a record for vaccine development. But the pandemic also showed that even this speed was not fast enough to prevent widespread transmission and millions of deaths.

The approval of an mRNA flu vaccine for seasonal use means that the manufacturing, regulatory, and distribution infrastructure for mRNA vaccines will be maintained and improved between pandemics, rather than being built from scratch during a crisis. This standing infrastructure could reduce the time to deploy a new mRNA vaccine in a pandemic from a year to months, or even weeks.

The seasonal mRNA flu vaccine also serves as a proof of concept for rapid response. If a novel pandemic influenza strain emerges, the mRNA platform allows the vaccine to be updated to target the new strain within weeks of its identification. The regulatory pathway, having been established for seasonal mRNA flu vaccines, could be streamlined for pandemic use. The combination of rapid design, established manufacturing, and a proven regulatory pathway could be decisive in the next pandemic.

07When mRNA flu vaccines will be available

The timeline for widespread availability of mRNA flu vaccines depends on manufacturing scale-up, distribution logistics, and public acceptance. The initial supply will be limited as production capacity expands, and priority may be given to high-risk populations, including older adults, pregnant women, and individuals with underlying health conditions.

Public acceptance of mRNA vaccines remains a consideration. While mRNA vaccines were administered to billions of people during the COVID-19 pandemic, some individuals remain hesitant about the technology. Education and transparent communication about how mRNA vaccines work, their safety profile, and their advantages over traditional vaccines will be important for achieving broad uptake.

The cost of mRNA vaccines, currently higher than traditional flu vaccines, is expected to decrease as production scales up and manufacturing processes improve. Over time, the mRNA flu vaccine could become the standard, replacing egg-based production for most seasonal influenza vaccination. The transition will depend on demonstrating cost-effectiveness, building public trust, and ensuring equitable access across populations.